FDA Accepts Regeneron Odronextamab Resubmission for Follicular Lymphoma Review
Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended...
Jon Napitupulu
Emalex Biosciences Tourette Syndrome Study Meets Endpoints
Emalex Biosciences’ Phase 3 trial of ecopipam, a dopamine-1 receptor antagonist, demonstrated statistically significant improvement in Tourette syndrome symptoms...
TNF Pharmaceuticals Launches Phase 2b Trial of Oral TNF Inhibitor
TNF Pharmaceuticals has initiated a fully funded Phase 2b clinical trial for isomyosamine, an oral TNF-α inhibitor, targeting muscle...
Coya Therapeutics in BTIG KOL Call on Alzheimer’s & GLP-1
Coya Therapeutics is advancing COYA 303, a combination therapy of low-dose interleukin-2 (COYA 301) and a GLP-1 receptor agonist,...
Castle Creek Biosciences Secures $75M Royalty Financing
Ligand Pharmaceuticals has invested $50 million and led a syndicate of co-investors, including Paragon Biosciences, Valor Equity Partners, and...
Oric Pharmaceuticals Announces Development Plans, Cash Runway, and Milestones
ORIC Pharmaceuticals announced focused development plans for its lead programs, ORIC-944 and ORIC-114, extending its cash runway into 2027....
FDA Accepts Medincell and Teva Uzedy for Bipolar I Disorder Treatment
Teva Pharmaceuticals and Medincell announced that the FDA accepted their supplemental New Drug Application for UZEDY, a long-acting injectable...
Elixirgen Therapeutics First Gene Therapy Trial Shows Telomere Elongation
Elixirgen Therapeutics announced positive Phase 1/2 clinical trial data for EXG-34217, a novel therapy for Telomere Biology Disorders (TBDs)....
Trethera & UCLA Publish Data on TRE-515 in Mice with MS
Trethera Corporation announced research published in Immunology demonstrating that their drug, TRE-515, effectively inhibits the hyperactive lymphocytes responsible for...
FemBloc Permanent Birth Control: Positive Safety and Efficacy Results
Femasys Inc. announced positive clinical trial data for FemBloc, a non-surgical permanent birth control method, published in the Journal...